- Vaxcyte, Inc. recently reported second-quarter 2026 results showing a wider net loss of US$284.3 million and higher basic loss per share, while also updating investors on the progress of its vaccine pipeline.
- Alongside the larger first-half loss of US$604.92 million, management highlighted full enrollment of three pivotal VAX-31 adult Phase 3 trials and early-stage progress for VAX-A1 against Group A Streptococcus, underscoring the company’s heavy investment in late- and early-stage vaccine programs.
- We’ll now examine how completing enrollment in the three VAX-31 Phase 3 OPUS trials could influence Vaxcyte’s existing investment narrative.
AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Vaxcyte Investment Narrative Recap
To own Vaxcyte, you need to believe that its VAX-31 and VAX-A1 programs can eventually turn substantial R&D spending into a durable adult and pediatric vaccine franchise. The latest results reinforce the main near term catalyst as OPUS-1 Phase 3 data, while also highlighting the key risk that rising losses and cash usage could accelerate if timelines slip or outcomes disappoint. On their own, the wider losses do not yet appear to alter that near term focus.
Among the recent updates, the completion of enrollment across all three VAX-31 Phase 3 OPUS trials looks most relevant. It moves Vaxcyte closer to its planned biologics license application package and keeps the spotlight on OPUS-1’s head to head comparisons with Prevnar 20 and Capvaxive. For investors watching catalysts, this milestone frames the coming data readouts as the next major checkpoints for whether today’s heavy investment ultimately supports the longer term thesis.
Yet against that progress, the scale and pace of cash burn raises questions investors should be aware of if OPUS-1 or later studies were to...
Read the full narrative on Vaxcyte (it's free!)
Vaxcyte's narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies an earnings increase of about $794.7 million from -$766.6 million today.
Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 88% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts expected Vaxcyte to reach about US$423.8 million of revenue and roughly US$46.2 million of earnings by 2029, which is far more bullish than the baseline view and assumes strong follow through on OPUS progress and manufacturing build out, so this new data could easily shift how you weigh that potential against the added execution risk.
Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth just $109.00!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Vaxcyte research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Vaxcyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.
Curious About Other Options?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Find 50 companies with promising cash flow potential yet trading below their fair value.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com